Sanofi Highlights MS Asset After Solid Q4

BTK Inhibitor Entering Phase III Soon

 
• By Sten Stovall
Sanofi_Berlin
Sanofi is refocusing its business model and narrowing therapeutic priorities • Source: Shutterstock

More from Earnings

More from Business